Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients

Abacavir/Dolutegravir/Lamivudine Single-Tablet Regimen: A Review of Its Use in HIV-1 Infection

(2015) Sarah L. Greig et al.   DRUGS

Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients

(2015) Slim Fourati et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

(2015) José A Perez-Molina et al.   LANCET INFECTIOUS DISEASES

Will drug resistance against dolutegravir in initial therapy ever occur?

(2015) Mark A. Wainberg et al.   Frontiers in Pharmacology

Antiretroviral reduction

(2014) Jonathan Colasanti et al.   AIDS

Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1

(2014) Jeffrey L. Lennox et al.   ANNALS OF INTERNAL MEDICINE

Antiretroviral Treatment of Adult HIV Infection

(2014) Huldrych F. Günthard et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

(2014) A. Castagna et al.   JOURNAL OF INFECTIOUS DISEASES

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

(2014) Bonaventura Clotet et al.   LANCET

Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials

(2014) Jose Arribas et al.   Journal of the International AIDS Society

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

(2013) Pedro Cahn et al.   LANCET

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

(2011) Sherene Min et al.   AIDS

Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study

(2011) B. Hasse et al.   CLINICAL INFECTIOUS DISEASES